NEW YORK, April 24, 2017 /PRNewswire/ --
Ahead of today's trading session, Stock-Callers.com turns focus on the global Generic Drugs space, which was valued at around $228.8 billion in 2016. The biggest catalyst for growth is an increasing global pharmaceutical spending trend towards generics. For evaluation this morning are: Evoke Pharma Inc. (NASDAQ: EVOK), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Lannett Co. Inc. (NYSE: LCI), and Catalent Inc. (NYSE: CTLT). Register now and get full and free access to our downloadable research reports on these stocks at:
Solana Beach, California headquartered Evoke Pharma Inc.'s shares recorded a trading volume of 164,536 shares last Friday. The stock finished the trading session 5.41% lower at $2.45. The Company's shares have gained 7.36% over the previous three months and 21.29% since the start of this year. The stock is trading below its 200-day moving average by 5.15%. Furthermore, shares of Evoke Pharma, which focuses on the development of drugs for the treatment of gastroenterological disorders and diseases, have a Relative Strength Index (RSI) of 21.49.
On April 18th, 2017, Evoke Pharma announced that it has reached an agreement to work in partnership with Spaulding Clinical Research for its planned comparative exposure pharmacokinetic trial for its lead product candidate, Gimoti™, a patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women. Access our complete research report on EVOK for free at:
On Friday, San Diego, California headquartered Neurocrine Biosciences Inc.'s stock ended the session 0.80% lower at $51.10. A total volume of 882,404 shares was traded. The Company's shares have surged 22.48% in the last one month, 23.82% over the previous three months, and 32.04% on an YTD basis. The stock is trading 14.98% above its 50-day moving average and 10.97% above its 200-day moving average. Moreover, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US and internationally, have an RSI of 64.21.
On April 11th, 2017, Neurocrine Biosciences announced that the US FDA has approved INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective vesicular monoamine transporter 2 inhibitor, is the first and only FDA-approved product indicated for the treatment of adults with TD. The complimentary research report on NBIX can be downloaded at:
Philadelphia, Pennsylvania-based Lannett Co. Inc.'s stock ended the day 0.82% lower at $24.25 with a total trading volume of 372,656 shares. The Company's shares have gained 16.31% in the last month, 25.65% over the previous three months, and 9.98% on an YTD basis. The stock is trading 7.66% above its 50-day moving average. Additionally, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 54.45.
On March 30th, 2017, Lannett announced that it voluntarily made a $25 million payment against its existing revolving credit facility. The payment, combined with the $75 million payment the Company made earlier this year in January, will save Lannett approximately $5.5 million in annualized cash interest expense at current rates. Register for free on Stock-Callers.com and get access to the latest PDF format report on LCI at:
Shares in Somerset, New Jersey headquartered Catalent Inc. recorded a trading volume of 410,276 shares. The stock ended Friday's session 0.74% lower at $28.08. The Company's shares have gained 7.13% over the previous three months and 4.15% since the start of this year. The stock is trading above its 200-day moving average by 7.87%. Furthermore, shares of Catalent, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, have an RSI of 48.47.
On April 17th, 2017, Catalent announced that it will release financial results for Q3 FY17 ended March 31st, 2017 after the market close on Thursday, May 04th, 2017. The Company's management will host a webcast to discuss the results at 4:45 p.m. ET on the same day. The webcast will be accessible on the Company's website. Download your free research report on CTLT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA